Vanguard Group Inc Anavex Life Sciences Corp. Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
A detailed history of Vanguard Group Inc transactions in Anavex Life Sciences Corp. stock. As of the latest transaction made, Vanguard Group Inc holds 5,106,867 shares of AVXL stock, worth $55.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,106,867
Previous 4,902,246
4.17%
Holding current value
$55.1 Million
Previous $42.1 Million
11.94%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding AVXL
# of Institutions
195Shares Held
31.8MCall Options Held
1.16MPut Options Held
804K-
Black Rock Inc. New York, NY6.39MShares$68.9 Million0.0% of portfolio
-
State Street Corp Boston, MA2.95MShares$31.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.02MShares$21.8 Million0.0% of portfolio
-
Nwam LLC Mercer Island, WA1.02MShares$11 Million0.83% of portfolio
-
Two Sigma Investments, LP New York, NY973KShares$10.5 Million0.02% of portfolio
About ANAVEX LIFE SCIENCES CORP.
- Ticker AVXL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,942,800
- Market Cap $840M
- Description
- Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...